Publication Type: Peer-Reviewed
-
Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat® Good versus VeriStrat® Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
-
Cost-effectiveness of an autoantibody test as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules
-
Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer
-
Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer
-
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
-
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
-
A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules
-
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIB/IV Non–Small-Cell Lung Cancer
-
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer
-
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation